News
PRESS RELEASE – ISO9001 certification
Genoskin obtains ISO9001 certification The entire Genoskin team is proud to announce that we obtained the ISO9001:2015 certification in January 2017. This certificate validates the quality and consistency of our design and R&D services as well as the commercialization of human skin models, cells and tissues to pharmaceutical, chemical and cosmetic industries. Consistent quality for skin models and R&D programs The
Genoskin launches new website
September 2016. After several months of hard work and dedication, we are thrilled to officially announce the launch of our new website! We invite you to visit us at www.genoskin.com We have built our new website with you in mind. The streamlined user interface provides a more interactive experience, allowing our colleagues, partners, clients and prospects to easily find the information
Genoskin is a winner of the 7th edition of the NETVA contest: See you soon in Boston !
The NETVA (New Technology Venture Accelerator) program consists in a preparation and exposure to high-tech US markets for young innovative French companies. It is run by the Office for Science & Technology of the Embassy of France in the United States in three locations: Boston, San Francisco and Washington, DC. Each year, 15 French startups are selected though a national competition
Genoskin presents new skin cancer model at Meet2Win
Genoskin launches new OncoSkin® skin cancer model at Meet2Win Genoskin has developed a new skin cancer model for the in vitro study of melanoma. Patients who suffer from this highly dangerous type of skin cancer currently have limited therapeutic options when the cancer reaches metastasis. The OncoSkin® skin cancer model now enables in vitro studies on live melanoma spheroids implanted
Oriflame study uses NativeSkin® human skin explant model
NativeSkin®, a novel skin explant model for skin delivery assessment The Genoskin team is proud to announce that Oriflame Cosmetics published an article in the March 2015 edition of Cosmetics & Toiletries under the title “A Novel Skin Explant Model For Skin Delivery Assessment”. The work presented in this article was conducted by Oriflame’s cosmetics experts in their facility in Stockholm. Genoskin has
Genoskin develops and markets innovative testing tools to study the effects of pharmaceutical, cosmetic and chemical products on real, live ex vivo human skin.
